전체 연도 결과 공지
08 4월 2024
데스티니 파마 plc
("Destiny Pharma" 또는 "회사")
연간 실적 통지 및 투자자 설명회
브라이튼, 영국 - Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, will announce its financial results for the year ended 31 December 2023, on Thursday 25 April 2024.
Chris Tovey, Chief Executive Officer, and Shaun Claydon, Chief Financial Officer, will host a briefing for analysts at 8.30am BST followed by a presentation to all existing and potential shareholders at 11:00am BST held via the Investor Meet Company platform. Further details for the analyst briefing will be shared by invitation in due course.
Questions can be submitted pre-event via the Investor Meet Company dashboard up until 09:00am BST the day before the meeting, or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free, and add to meet Destiny Pharma
plc via: https://www.investormeetcompany.com/destiny-pharma-plc/register-investor
Investors who already follow Destiny Pharma plc on the Investor Meet Company platform will automatically be invited.
자세한 내용은 문의하시기 바랍니다 :
데스티니 파마 plc
크리스 토비, CEO
숀 클레이던, CFO
+44 (0)1273 704 440
FTI 컨설팅
Ben Atwell / Simon Conway / Michael Trace
+ 44 (0) 203 727 1000
쇼어 캐피탈(지명 고문 및 Broker)
다니엘 부시 / 제임스 토마스 / 루시 보든
+ 44 (0) 207 408 4090
데스티니 파마 소개
Destiny Pharma is an innovative, clinical-stage biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections. The company's drug development pipeline includes two late stage assets NTCD-M3, a microbiome-based biotherapeutic for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US, and XF-73 nasal gel, a proprietary drug targeting the prevention of post-surgical staphylococcal hospital infections including MRSA.
회사에 대한 자세한 내용은 www.destinypharma.com을 방문하세요.
RNS는 귀하의 IP 주소를 사용하여 약관 준수 여부를 확인하고, 귀하가 이 커뮤니케이션에 포함된 정보를 사용하는 방식을 분석하고, 그러한 분석을 익명으로 다른 사람과 상용 서비스의 일부로 공유할 수 있습니다. RNS와 런던 증권 거래소가 귀하가 제공한 개인 데이터를 사용하는 방법에 대한 자세한 내용은 개인 정보 보호 정책을 참조하십시오.